HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Gain Therapeutics (NASDAQ:GANX) and maintained a price target of $9.
May 15, 2024 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Gain Therapeutics and maintained a price target of $9, indicating continued confidence in the company's potential.
The reiteration of a Buy rating and the maintenance of a $9 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and could lead to a short-term increase in GANX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100